

Curriculum Vitae

Personal Data

Title	Prof. Dr. med.
First name	Juliane Sarah
Name	Walz née Stickel
Current position	W3 Professor for Peptide-based Immunotherapy and Medical Director Clinical Cooperation Unit (CCU) Translational Immunology and Head of the Wirkstoffpeptidlabor (GMP peptide production facility), Department of Immunology, University of Tübingen, Germany
Current institution(s)/site(s), country	University and University Hospital Tübingen, Germany
Identifiers/ORCID	0000-0001-6404-7391

Qualifications and Career

Stages	Periods and Details
Degree programme	2004 – 2010 , Medical School, Tübingen, Germany
Doctorate	2011 , M.D. (summa cum laude), Medical Faculty / Department of Immunology, University of Tübingen, Germany 2010 , Approbation (physicians license), Medical Faculty, University of Tübingen, Germany
Stages of academic/professional career	Since 2022 , W3 Professor for Peptide-based Immunotherapy and Medical Director Clinical Cooperation Unit (CCU) Translational Immunology, Tübingen Since 2020 , Head of the Wirkstoffpeptidlabor (GMP peptide production facility), Department of Immunology, University of Tübingen, Germany 2020 – 2022 , Head of Immunotherapy Robert Bosch Cancer Centre, Stuttgart, Germany 2020 – 2022 , Senior physician CCU Translational Immunology, University Hospital Tübingen, Germany 2019 – 2020 , Senior physician Department of Hematology and Oncology, University Hospital Tübingen, Germany 2019 , Research scholarship, National Institute of Health (NIH), Bethesda, USA

	2018, Specialist Physician Department of Hematology and Oncology, University Hospital Tübingen, Germany 2018, Habilitation (Internal Medicine), Medical Faculty, University of Tübingen, Germany 2017, Specialist for Internal Medicine and Hematology and Oncology, District Medical Association of South Wuerttemberg, Germany 2012 – 2022, Research group leader, Department of Immunology, University of Tübingen, Germany 2011 – 2017, Resident Department of Hematology and Oncology, University of Tübingen, Germany
--	---

Supplementary Career Information

Married

Children

D.O.B.: son, 25.06.2018

Maternity leave May 5, 2018 - February 26, 2019 (6 months full time, 4 months part-time 50%)

D.O.B.: daughter, 16.01.2023

Maternity leave: 29.11.22 - 15.03.23

Activities in the Research System

Since 2023	Board member of the Comprehensive Cancer Center “CCC” Tübingen-Stuttgart
Since 2022	Member of the Board of Trustees of the Leibniz Institute for Immunotherapy, Regensburg University Hospital
Since 2022	Deputy site spokesperson of the German Consortium for Translational Cancer Research (DKTK)
Since 2021	Member of the National Center for Tumor Diseases SouthWest (writing and presenting committee)
Since 2021	Member of the Technology Transfer Task Force of the Medical Faculty, University of Tübingen, Germany
Since 2020	Member of the research commission of the Medical Faculty, University of Tübingen, Germany
Since 2018	Member of the Executive Board (leading board of 4 members), “iFIT” Cluster of Excellence, Medical Faculty, University of Tübingen, Germany
Since 2018	Faculty member, Medical Faculty, University of Tübingen, Germany

Reviewer for Member Advisory Board Science Translational Medicine, Reviewer for Research Fund Application, José Carreras Leukemia Foundation, Reviewer for European Research Council ERC-2021-Consolidator Grant (CoG), Reviewer for Research Fund Applications, Federal Ministry for Education and Research (BMBF), Germany, Review activities for leading scientific journals e.g. Science, Science Translational Medicine, Nature Immunology, Cancer Discovery, Science Immunology, Blood, Cell Host Microbe

Supervision of Researchers in Early Career Phases

Presently	Active Lecturer in 2 lecture series, 4 seminars and 1 practical course in the field of immunology, oncology and infectiology at the Faculty of Science and Faculty of Medicine, University of Tübingen, Germany
Since 2021	Course responsible Master seminar “Selected Topics in Oncology”
Since 2018	Representative for Equal Opportunities and Early Career “iFIT” Cluster of Excellence
2017	Medical didactic qualification certificate

Scientific Results

10 most important publications

Goyal A, Bauer J, Hey J, Papageorgiou DN, Stepanova E, Daskalakis M, Scheid J, Dubbelaar M, Klimovich B, Schwarz D, Märklin M, Roerden M, Lin YY, Ma T, Mücke O, Rammensee HG, Lübbert M, Puch FL, Krijgsveld J, **Walz JS***, Plass C*. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. *Nat Commun.* 2023 Oct 23;14(1):6731. doi: 10.1038/s41467-023-42417-w.

* equal senior authorship

Maringer Y, Nelde A, Schroeder SM, Schuhmacher J, Hörber S, Peter A, Karbach J, Jäger E, **Walz JS**. Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. *Science Immunol.* 2022 Nov 1:eadd3899. doi: 10.1126/sciimmunol.add3899

Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luijbrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, **Walz JS**. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. *Nat Commun.* 2022, 13, 6401. <https://doi.org/10.1038/s41467-022-33746-3>

Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Karbach J, Jäger E, Klein R, Rammensee HG, Salih HR, **Walz JS**. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. *Nature* 2022 Jan;601(7894):617-22. doi: 10.1038/s41586-021-04232-5.

Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar MS, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HGR, Salih HR, **Walz JS** (2021). Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. *Cancer Discov.* 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191.

Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Rachfalski D, Märklin M, Stevanović S, Rammensee HG, Salih HR, **Walz JS**. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. *Sci Transl Med.* 2021 Apr 21;13(590):eabf7517. doi: 10.1126/scitranslmed.abf7517.

Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert S, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, **Walz JS** (2020). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T-cell recognition. *Nature Immunol.* 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x

Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M, Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, **Walz JS**. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. *Nat Commun.* 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0.

Bilich T*, Nelde A*, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, **Walz JS** (2018). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. *Blood.* 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830.

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanović S, **Stickel JS** (2015). HLA ligandome analysis identifies the underlying specificities of spontaneous anti-leukemia immune responses in chronic lymphocytic leukemia (CLL). *Proc Natl Acad Sci U S A.* 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112.

Academic Distinctions

2022	Best Abstract Award, German Society of Hematology and Oncology, Wien
2022	International Immunocompromised Host Society (ICHS) Takeda Virology Award
2021	Best Abstract Award, German Society of Hematology and Oncology, Berlin
2020, 2017	Poster Award, University of Tübingen, research colloquium (2 awards)
2019	Research scholarship, National Institute of Health (NIH)
2019	Fellowship Haematokolleg of the Competence Network Malignant Lymphoma e.V.
2018, 2015	Poster Award, German Society of Hematology and Oncology (2 awards)
2016	Young Investigator Award, German Society of Hematology and Oncology, Leipzig
2015	Wuerttemberg Cancer Award, Dres. Carl Maximilian und Carl Manfred Bayer-Stiftung
2012 - 2014	Abstract Achievement Award, American Society of Hematology (3 awards)
2011	MD Award, University of Tübingen
2011	Ludolf Krehl Award, South German Society for Internal Medicine